Insider Selling: Artivion, Inc. (NYSE:AORT) Insider Sells 6,457 Shares of Stock

Artivion, Inc. (NYSE:AORT) insider John E. Davis sold 6,457 shares of Artivion stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $176,340.67. Following the transaction, the insider now owns 160,631 shares of the company’s stock, valued at $4,386,832.61. The trade was a 3.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Artivion Stock Down 0.5 %

NYSE AORT opened at $25.44 on Thursday. The business has a fifty day moving average price of $29.68 and a 200 day moving average price of $27.83. Artivion, Inc. has a one year low of $18.38 and a one year high of $32.33. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The company has a market cap of $1.07 billion, a P/E ratio of -1,272.00 and a beta of 1.75.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Institutional Trading of Artivion

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP grew its holdings in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after purchasing an additional 820 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the period. R Squared Ltd purchased a new position in shares of Artivion during the 4th quarter worth $39,000. Arcadia Investment Management Corp MI purchased a new position in shares of Artivion during the 4th quarter worth $43,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Artivion during the 4th quarter valued at about $64,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Stifel Nicolaus decreased their price objective on Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Needham & Company LLC cut their price objective on Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Oppenheimer upped their target price on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.